Umeclidinium bromide/vilanterol

Last updated

Umeclidinium bromide/vilanterol
Umeclidinium bromide and vilanterol.svg
Umeclidinium bromide (TOP), vilanterol (BOTTOM)
Combination of
Umeclidinium bromide Muscarinic antagonist
Vilanterol Ultra-long-acting β2 agonist
Clinical data
Trade names Anoro Ellipta, others
AHFS/Drugs.com Professional Drug Facts
License data
Pregnancy
category
  • AU:B3
Routes of
administration 		Inhalation
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Umeclidinium bromide/vilanterol, sold under the brand name Anoro Ellipta, among others, is a fixed-dose combination medication for the treatment of chronic obstructive pulmonary disease (COPD). [5] [6] It is administered by inhalation.

The most common side effects include upper respiratory tract infections, urinary tract infections, pharyngitis, sinusitis, nasopharyngitis, headache, cough, oropharyngeal pain, constipation and dry mouth. [4]

In 2022, it was the 211th most commonly prescribed medication in the United States, with more than 1 million prescriptions. [7] [8]

References

  1. ↑ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
  2. ↑ "Anoro Ellipta 55 micrograms/22 micrograms inhalation powder, pre-dispensed - Summary of Product Characteristics (SmPC)". (emc). 7 October 2019. Retrieved 29 October 2020.
  3. ↑ "Anoro Ellipta- umeclidinium bromide and vilanterol trifenatate powder". DailyMed. 2 June 2023. Retrieved 24 November 2024.
  4. 1 2 "Anoro Ellipta EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 28 October 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. ↑ Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID   24004659. S2CID   5744282.
  6. ↑ "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. 18 December 2013.
  7. ↑ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  8. ↑ "Umeclidinium; Vilanterol Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.